Search Results - "Gerratana L"

This result is not displayed to guests.
Login for full access.

7PMonocyte-to-lymphocye ratio (MLR) and LDH level in metastatic colorectal cancer (mCRC) patients (pts).

Authors: Basile, D Gerratana, L Corvaja, C et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

302PA risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients.

Authors: Pelizzari, G Gerratana, L Basile, D et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

Chest computed tomography of trastuzumab-deruxtecan (T-DXd)-related interstitial lung disease: Key points for radiologists.

Authors: Cereser, L. Della Rossa, S. Sparascio, F. et al.

Source: European Journal of Radiology. Jan2026, Vol. 194, pN.PAG-N.PAG. 1p.

498P Impact of estrogen receptor expression on real-world effectiveness of first-line ET+CDK4/6i in patients with HR+/HER2- advanced BC.

Authors: Vernieri, C. Dieci, M.V. Caputo, R. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS408-S409. 2p.

P-266 LDH levels as predictors of efficacy in second-line treatment for metastatic gastric cancer: The LINE study.

Authors: Michelotti, A. Ongaro, E. Gerratana, L. et al.

Source: Annals of Oncology. 2020 Supplement 3, Vol. 31, pS176-S177. 2p.

2342P IN.C.L.U.D.E.: An Italian study on inclusion of LGBTQIA+ oncology healthcare professionals and equity dynamics in the workplace.

Authors: Belluomini, L. Viscardi, G. Occhipinti, M. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1281-S1281. 1p.

522P Resistance mutational profiles and prognostic implications by different type of first-line CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (mBC): A liquid biopsy analysis.

Authors: Zapelloni, G. De Angelis, C. Giudici, F. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS420-S420. 1p.

504P Temporal dynamics of ESR1 mutations (ESR1m) and AKT pathway (AKTp) co-alterations at first-line (1L) progression in HR+ HER2- metastatic breast cancer: Defining optimal diagnostic windows.

Authors: Foffano, L. De Angelis, C. Giudici, F. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS411-S411. 1p.

582P Prognostic role of macrophage infiltration and monocyte-to-lymphocyte ratio in stage III colon cancer: The MIRROR study.

Authors: Basile, D. Polano, M. Di Nardo, P. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS471-S472. 2p.

414P The complex relationship between circulating tumor cells (CTCs) and brain metastases (BMs) in metastatic breast cancer (mBC): A retrospective pooled analysis.

Authors: Pastò, B. Pierga, J-Y. Fehm, T.N. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS393-S394. 2p.

415P Comprehensive liquid biopsy characterization of patients with metastatic inflammatory breast cancer.

Authors: Nicolo, E. Foffano, L. Molteni, E. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS394-S394. 1p.

416P Prognostic impact of liquid biopsy (LB) biomarkers at relapse on second-line (2L) treatment (Tx) after progression to endocrine therapy (ET) in metastatic breast cancer (mBC): Ancillary analysis of the MAGNETIC.1 study.

Authors: Dri, A. Foffano, L. Molteni, E. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS395-S395. 1p.

380P Assessing interstitial lung disease (ILD) risk in metastatic breast cancer (MBC): A comprehensive meta and network analysis of antibody-drug conjugates (ADCs) compared to available treatment options beyond first-line (1L).

Authors: Cucciniello, L. Giudici, F. Di Nardo, P. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS378-S378. 1p.

261P Liquid biopsy–based biomarkers for the characterization of hormone receptor-positive (HR+) HER2-Low metastatic breast cancer (mBC).

Authors: Bortot, L. Basile, D. Palmero, L. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS656-S657. 2p.

293P Exploring the interplay between tumor burden and liquid biopsy longitudinal evaluation in hormone receptor-positive, HER2-negative metastatic breast cancer (MBC).

Authors: Mazzeo, R. Bortot, L. Michelotti, A. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS492-S493. 2p.

187P Impact of oncotype DX on agreement and confidence in adjuvant treatment decision making in breast cancer.

Authors: Licata, L. Viale, G. Criscitiello, C. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS317-S318. 2p.

270P Defining clinico-pathological characteristics of HER2 positive metastatic breast cancer (MBC) patients experiencing radiologic complete response (rCR) in a nationwide real-world cohort.

Authors: Cucciniello, L. Blondeaux, E. Bighin, C. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS661-S661. 1p.

249P A retrospective analysis on capecitabine and vinorelbine combination in metastatic breast cancer: The MARCELLINO study.

Authors: de Scordilli, M. Bortot, L. Cucciniello, L. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS650-S650. 1p.

242P Investigating the risk of drug-induced interstitial lung disease in patients with metastatic breast cancer treated with antiHER2 regimens through a network meta-analysis approach.

Authors: Palmero, L. Siciliano, M.A. Di Nardo, P. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS648-S648. 1p.